CRISPR Therapeutics CRSP Treasury Stock, Value
Treasury Stock, Value at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockValue.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's treasury stock, value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's treasury stock, value?
- CRISPR Therapeutics (CRSP) reported treasury stock, value of $60K in Q1 2026.
- How has CRISPR Therapeutics's treasury stock, value changed year-over-year?
- CRISPR Therapeutics's treasury stock, value decreased by 3.2% year-over-year, from $62K to $60K.
- What is the long-term trend for CRISPR Therapeutics's treasury stock, value?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's treasury stock, value has grown at a -1.0% compound annual growth rate (CAGR), from $63K to $60K.
- What does treasury stock, value mean?
- This represents the cost of common shares that the company has repurchased from the open market and holds in its treasury. Treasury stock reduces total shareholders' equity and is often used for employee stock compensation plans or to return capital to shareholders. It is recorded as a contra-equity account.